TEM
Tempus AI, Inc. Class A Common StockTEM
TEM
About: Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Employees: 2,300
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
59% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 27
53% more call options, than puts
Call options by funds: $78.1M | Put options by funds: $51.2M
42% more capital invested
Capital invested by funds: $1.49B [Q2] → $2.12B (+$629M) [Q3]
28% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 18
20% more funds holding
Funds holding: 80 [Q2] → 96 (+16) [Q3]
20% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]
1.46% less ownership
Funds ownership: 26.66% [Q2] → 25.2% (-1.46%) [Q3]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$52
9%
upside
Avg. target
$62
29%
upside
High target
$74
55%
upside
7 analyst ratings
4 positive
57%
3 neutral
43%
0 negative
0%
Loop Capital Mark Schappel 81% 1-year accuracy 25 / 31 met price target | 9%upside $52 | Buy Maintained | 14 Jan 2025 |
Needham Ryan MacDonald 56% 1-year accuracy 38 / 68 met price target | 18%upside $56 | Buy Reiterated | 14 Jan 2025 |
B of A Securities Michael Ryskin 75% 1-year accuracy 3 / 4 met price target | 13%upside $54 | Neutral Maintained | 13 Dec 2024 |
Wolfe Research Doug Schenkel 20% 1-year accuracy 1 / 5 met price target | 26%upside $60 | Outperform Initiated | 13 Dec 2024 |
Guggenheim Subbu Nambi 40% 1-year accuracy 4 / 10 met price target | 55%upside $74 | Buy Initiated | 9 Dec 2024 |
Financial journalist opinion
Based on 20 articles about TEM published over the past 30 days
Positive
The Motley Fool
3 hours ago
Why Tempus Ai Stock Is Skyrocketing Today
Tempus Ai (TEM 33.70%) stock is seeing an explosive valuation surge in Tuesday's trading thanks to a pair of catalysts. The healthcare software company's share price was up 35.8% as of 3:15 p.m.
Positive
Seeking Alpha
4 hours ago
Tempus AI Has A High Probability Of Profitability In 2025
Tempus AI, Inc. is projected to achieve 30% YoY top line growth in Q4 2024 as presented in management's preliminary results. Growth is forecast to continue in the 23-25% range in eFY25. Tempus is expecting to close the Ambry acquisition in Q1 2025. The deal will be accretive to Tempus' adjusted EBITDA margin while maintaining its high-growth trajectory. Tempus recently gained in-network provider status with Blue Cross Blue Shield across multiple states, allowing for the firm's tests to be covered by insurance.
Positive
Proactive Investors
5 hours ago
Tempus AI jumps almost a third on health app launch
Tempus AI Inc shares skyrocketed on Tuesday after the company announced the nationwide launch of its personal health app. Known as Olivia, the app was designed to centralize patients' health data and make it accessible and actionable using artificial intelligence, Tempus said in a statement.
Positive
Barrons
9 hours ago
This Medical AI Stock Is Up 30% After Launch of Personal Health App
Tempus AI says the app, olivia, is designed to centralize patients' health data and make it accessible through artificial intelligence.
Neutral
Business Wire
11 hours ago
Tempus Announces National Launch of olivia, its AI-enabled Personal Health Concierge App for Patients
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of olivia. olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI to provide actionable insights. olivia is designed to address two core objectives – centralizing patients' health data and ma.
Neutral
Business Wire
6 days ago
Tempus Announces the National Launch of FDA-Approved xT CDx Test
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company's FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved test that delivers comprehensive insights with one of the largest reported gene panels available. xT CDx is a 648-gene next-gen.
Positive
Seeking Alpha
6 days ago
Tempus AI: Disappointing Q4 Preliminary Results, But Bullish Fundamental Update
Tempus AI is a leading player in healthcare AI, aiming to deliver personalized treatment suggestions through its proprietary data model. Preliminary Q4 results and 2025 guidance show mixed performance, with revenue slightly below expectations but positive adjusted EBITDA anticipated for 2025, driven by the Ambry Genetics acquisition. TEM's strong fundamentals and competitive position, bolstered by the Ambry acquisition, support long-term growth, particularly in diagnostics and expanding AI applications across healthcare.
Neutral
Zacks Investment Research
1 week ago
TEM Stock Declines Following Preliminary Q4 Sales Miss
Tempus reports strong 2024 growth and unveils a bold 2025 outlook with 75% revenue growth and innovative diagnostics.
Neutral
Business Wire
1 week ago
Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities available in Tempus One, the company's generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled services that leverage generative AI to propel privacy-enabled, data-driven decision support in the clinic while simultaneo.
Neutral
Business Wire
1 week ago
Tempus Announces Its First-Ever, Whole-Genome Sequencing Assay, xH
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is developing its first whole-genome sequencing test, xH. This test marks Tempus' first foray into adopting whole-genome sequencing (WGS) as a platform, supporting clinicians with detection of all clinically-relevant variants and advancing the landscape of personalized therapy, specifically in hematological oncology.
Charts implemented using Lightweight Charts™